The actin cytoskeleton inhibits pore expansion during PIV5 fusion protein-promoted cell–cell fusion  by Wurth, Mark A. et al.
Virology 404 (2010) 117–126
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roThe actin cytoskeleton inhibits pore expansion during PIV5 fusion protein-promoted
cell–cell fusion
Mark A. Wurth a, Rachel M. Schowalter a, Everett Clinton Smith a, Carole L. Moncman a,
Rebecca Ellis Dutch a,⁎, Richard O. McCann b
a Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington KY 40536, USA
b Mercer University School of Medicine, Division of Basic Medical Sciences, Macon, GA 31207, USA⁎ Corresponding author. Department of Molecula
University of Kentucky, College of Medicine, Biomedica
Building, 741 South Limestone, Lexington, KY 40536-050
E-mail address: rdutc2@uky.edu (R.E. Dutch).
0042-6822/$ – see front matter © 2010 Elsevier Inc. A
doi:10.1016/j.virol.2010.04.024a b s t r a c ta r t i c l e i n f oArticle history:
Received 21 April 2010
Accepted 22 April 2010
Keywords:
Paramyxovirus
Fusion protein
Membrane fusion
Syncytia
CytoskeletonParamyxovirus fusion (F) proteins promote both virus–cell fusion, required for viral entry, and cell–cell fusion,
resulting in syncytia formation.We used the F-actin stabilizing drug, jasplakinolide, and the G-actin sequestrant,
latrunculin A, to examine the role of actin dynamics in cell–cell fusion mediated by the parainﬂuenza virus 5
(PIV5) F protein. Jasplakinolide treatment caused a dose-dependent increase in cell–cell fusion as measured by
both syncytia and reporter geneassays, and latrunculinA treatmentalso resulted in fusion stimulation. Treatment
with jasplakinolide or latrunculinApartially rescued a fusionpore opening defect causedbydeletion of the PIV5 F
protein cytoplasmic tail, but these drugs had no effect on fusion inhibited at earlier stages by either temperature
arrest or by a PIV5 heptad repeat peptide. These data suggest that the cortical actin cytoskeleton is an important
regulator of fusion pore enlargement, an energetically costly stage of viral fusion protein-mediated membrane
merger.r and Cellular Biochemistry,
l Biological Sciences Research
9, USA. Fax: +1 859 323 1037.
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The family Paramyxoviridae contains a number of important human
pathogens. Measles remains an important cause of childhood mortality
in the developing world, killing an estimated 345,000 children in 2005
alone (Wolfson et al., 2007). Respiratory syncytial virus (RSV) is the
most common cause of hospitalization of infants and children in the
United States (Black, 2003). Nipah virus ﬁrst emerged in Malaysia and
Singapore during 1998/9, resulting in an epidemic of encephalitis with
105 deaths from 265 reported cases (Chua et al., 1999; Paton et al.,
1999). A series of more recent outbreaks of Nipah virus have been
observed in southern and central Bangladesh, with higher mortality
rates compared to the 1998 outbreak (up to 70%), and documented
cases of human-to-human transmission (Eaton et al., 2006). The
paramyxovirus family also contains animal pathogens, including
parainﬂuenza virus 5 (PIV5), which causes respiratory infection in
canines and also infects humans asympotomatically (Goswami et al.,
1984; McCandlish et al., 1978).
Most paramyxoviruses have two major envelope glycoproteins that
are essential for viral pathogenesis (Lamb and Parks, 2007). The
attachment protein (HN, H, or G) binds to a viral receptor on the
plasma membrane of the host cell and is hypothesized to triggeractivation of the fusion protein (F). Conformational changes in the F
protein then drive the merger of the viral envelope with the host cell
membrane (Lamb and Jardetzky, 2007). Infection of host cells leads to
expression of the viral fusion and attachment proteins at the plasma
membrane. Cell surface expression of these viral proteins leads to fusion
between adjacent cell membranes, as the cellular receptors on
neighboring cells can be engaged by the fusion complex. As a result,
multinucleated giant cells (termed syncytia), are observed in infections
with many paramyxoviruses (Makino et al., 1994; Meyerholz et al.,
2004; Paterson et al., 1998).
Paramyxovirus fusion proteins contain a series of conserved
structural elements that are critical to the conformational rearrange-
ments required to drive membrane fusion (Dutch et al., 2000). These
type I integral membrane proteins are synthesized as polypeptide
precursors that trimerize in theendoplasmic reticulum,with subsequent
proteolytic processing of the precursor protein required for the protein
to become fusogenically active (Garten et al., 1994; Pager and Dutch,
2005; Scheid and Choppin, 1974). Proteolytic cleavage results in
placement of a hydrophobic region termed the fusion peptide at the
newly created N-terminus. Upon triggering, the fusion peptide is
released and inserted into the target membrane, resulting in a
conformation that bridges the two membranes (Asano and Asano,
1985; Novick and Hoekstra, 1988) (Fig. 1). Preventing activation of the
fusion protein by inhibiting receptor binding or lowering the temper-
atureblocks fusionupstreamof this bridgingconformation (Russell et al.,
2001). These fusion proteins contain two highly conserved heptad
repeat regions which do not interact in the prefusion form of the F
Fig. 1. Schematic representation of paramyxovirus F protein-promoted membrane fusion. A. Initial conformational changes lead to insertion of the fusion peptide into the target
membrane, a step that is blocked by incubation at low temperature. B. Subsequent refolding leads to formation of a six-helix bundle, bringing the fusion peptide and the
transmembrane domain regions into close proximity. This step can be blocked by addition of peptides corresponding to either of the heptad repeat regions. C. The fusion pore
expands to allow passage of larger molecules. This step is affected by truncation of the cytoplasmic tail of the PIV5 F protein. Yellow=fusion peptide; dark blue=heptad repeat A;
red=heptad repeat B; grey=transmembrane domain.
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formanextremely stable six-helixbundle (Baker et al., 1999;Dutchet al.,
1999). This bundle is observed in the post-fusion form of the F protein
following conformation rearrangements associated with fusion (Yin
et al., 2005) (Fig. 1). Formation of this stable helical bundle brings the
transmembranedomain and the fusion peptide into closeproximity, and
is hypothesized to provide at least a portion of the energy required for
membrane fusion (Baker et al., 1999). Treatment with high concentra-
tions of peptides corresponding to either of the heptad repeat regions
disrupts the formation of the six-helix bundle and effectively blocks
fusion (Russell et al., 2001). Following six-helix bundle formation and
initial pore formation, expansion of the fusion pore must occur. This
expansion step is hypothesized to be the most energetically costly stage
of the membrane fusion process (Chernomordik et al., 2006). Interest-
ingly, truncation of the cytoplasmic tail of the PIV5 protein signiﬁcantly
abrogated pore enlargement (Dutch and Lamb, 2001).
While extensive characterization of viral fusion proteins has led to a
model of F protein-mediated membrane fusion, much less is known
about the contribution of target membranes and their associated
proteins to fusion events. Lying just under the plasma membrane and
intimately associated with it through a complex series of adaptor
proteins is a dense network of actin ﬁlaments and associated proteins.
Results from various non-viral fusion systems, including analysis of
myoblast fusion and fusion events in exocytosis and endocytosis,
suggest that the cortical actin cytoskeleton may be a modulator of
membrane fusion events (Chernomordik et al., 2006; Eitzen, 2003;
Richardson et al., 2008), however, the mechanism of action remains
unclear. Studies of Drosphila myoblast fusion (Richardson et al., 2007),
fusion during exocytosis (Muallem et al., 1995) and fusion between
erythrocytes (Chernomordik and Sowers, 1991) have provided evi-
dence that the actin cytoskeleton inhibits fusion by acting as a stiff
scaffold preventing the deformation of themembrane required to allow
lipid mixing or pore enlargement. However, other studies using similar
model systems have supported a model by which actin polymerization
stimulates fusion by generating force to drive the lipid membranes
together and enlarge the nascent fusion pore (Massarwa et al., 2007;
Zheng and Chang, 1991). Finally, recent research has implicated actin as
important in a prefusion priming step during myoblast fusion (Kim
et al., 2007).
Modulation of the actin cytoskeleton appears to also affect cell–cell
fusion promoted by viral fusion proteins. RSV F protein-mediated
syncytia formation was inhibited both by pharmacological treatments
whichalter the cytoskeleton (Kallewaard et al., 2005) andbyClostridium
C3 toxin (Gower et al., 2005), an inhibitor of the RhoA protein which
regulates the dynamic behavior of the actin cytoskeleton at the plasma
membrane (Bishop and Hall, 2000). HIV env protein-promoted cell
fusion was inhibited by both latrunculin A and jasplakinolide (Pontowet al., 2004). We have shown that transfection of various constitutively
active Rho-family GTPases either stimulated or inhibited cell–cell fusion
induced by paramyxovirus fusion proteins in a manner that is cell type
speciﬁc, and dependent onwhether the proteinwas expressed in target
or effector cell populations (Schowalter et al., 2006). Two recent studies
of cell–cell fusion mediated by the inﬂuenza hemagglutinin (HA)
protein (Richard et al., 2009) and the baculovirus gp64 protein (Chen
et al., 2008) have addressed the potential role of actin. Data from the
study of inﬂuenza HA-promoted fusion pore formation found no
evidence for a role for actin in driving pore expansion, instead providing
some evidence that the actin cytoskeleton restricts pore expansion
(Richard et al., 2009). Results from the gp64 study strongly indicated
that the actin network is a barrier to fusion pore expansion (Chen et al.,
2008).
To shed further light on the role of the actin cytoskeleton in
membrane fusion, we have used various concentrations of latrunculin A
and jasplakinolide to perturb the actin cytoskeleton during paramyxo-
virus glycoprotein-mediated membrane fusion. Latrunculin A depoly-
merizes cytoplasmic actin by binding to and sequestering actin
monomers (Coue et al., 1987). Jasplakinolide stabilizes existing actin
ﬁlaments andnucleates ectopic actin polymerization (Bubb et al., 1994).
Both drugs stimulated fusion induced by the PIV5 F protein in a dose-
dependent manner at low concentrations. Experiments blocking fusion
at deﬁned points indicate that both drugs affect fusion after the stage of
six-helix bundle formation. Moreover, treatment with these drugs
partially rescued a mutant which is deﬁcient in pore enlargement,
suggesting that disregulation of the cortical actin cytoskeleton may
relieve a mechanical barrier to expansion of the nascent fusion pore.
Results
PIV5 F protein-mediated syncytia formation in the presence of
jasplakinolide or latrunculin A
Analysis of paramyxovirus F protein-mediated membrane fusion is
facilitated by the fact that expression of the viral attachment and fusion
proteins is sufﬁcient to induce cell–cell fusion events in tissue culture.
Formation ofmultinucleated giant cells, termed syncytia, from repeated
cell–cell fusion events provides a sensitive, but qualitative, measure of
the relative efﬁciency of membrane fusion promotion under varying
conditions.
To examine the effect of drugs which perturb the actin cytoskeleton
on thesemembrane fusion events, BHK cellswere transiently transfected
to express the PIV5 F and attachment (HN) proteins using the pCAGGS
expression system (Niwa et al., 1991). Following transfection, cells were
moved to media containing either the drug carrier (DMSO) or varying
concentrations of jasplakinolide, an F-actin stabilizing drug, or
Fig. 2. BHK-21 cells were transfected with pCAGGS PIV5 F and HN ormock transfected with empty pCAGGS vector. After transfection, cells were placed inmedia containing the described amount of jasplakinolide or latrunculin A. Syncytia were
imaged the following day.
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120 M.A. Wurth et al. / Virology 404 (2010) 117–126latrunculin A, a G-actin sequestrant. Syncytia formation was then
analyzed 24 h later.
Interestingly, treatment of cells with doses of up to 100 nM
jasplakinolide led to stimulation of syncytium formation by the PIV5
viral glycoproteins (Fig. 2), suggesting that perturbation of the actin
cytoskeleton can lead to increased cell–cell fusion. As concentrationswere
increasedbeyond150 nM, a relativedecrease in syncytium formationwas
observed, along with increasing cytotoxicity, marked cell rounding, and
loss of cell–cell contact (data not shown). The observed stimulation at
lower concentrations is in contrast to reports for HIV env-promoted
syncytia formation (Pontow et al., 2004), though the inhibition observed
at higher concentrations of jasplakinolide is consistent with results forFig. 3. Vero cells were transfected to express the PIV5 glycoproteins as described previously
Cells were ﬁxed in 4% paraformaldehyde, and stained with rhodamine–phalloidin and DAPI
aggregate formed due to ectopic polymerization and the asterisks identify a rufﬂed membrbothHIVenv-promotedsyncytia formation(Pontowetal., 2004)orRSVF-
promoted viral entry (Kallewaard et al., 2005).
In contrast, treatment with latrunculin A produced no consistent
changes in syncytia formation in cells expressing the PIV5 glycoproteins
(Fig. 2). Decreases in syncytia formation were again noted at higher
concentrations (data not shown), consistentwith reports from both the
HIV and RSV systems (Kallewaard et al., 2005; Pontow et al., 2004).
Actin structures in syncytium treated with jasplakinolide or latrunculin A
While jasplakinolidepromotes polymerizationof F-actin (Bubbet al.,
1994) and latrunculin A inhibits actin polymerization (Spector et al.,, and syncytia were allowed to develop in the presence of jasplakinolide or latrunculin.
. The arrows identify a stress ﬁber in the control cells. The arrowhead indicates an actin
ane in the latrunculin treated samples. Bar=10 µm.
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with either jasplakinolide (Bubb et al., 2000) or latrunculin (Wakatsuki
et al., 2001) can promote disordering of the cellular actin cytoskeleton,
likely due to reduction in the pool of free monomeric actin needed for
remodeling. To examine the speciﬁc effect of actin targeted drugs on the
cellular cytoskeleton in cells expressing the viral glycoproteins, we
induced syncytia formationusing the PIV5 glycoproteins in thepresence
and absence of drug as above. Cells were ﬁxed and stained with
rhodamine–phalloidin and DAPI. Nuclei in the syncytium of the treated
and untreated cells were almost exclusively found in an organized
structure in the center of the cell. Syncytia displayed robust stress ﬁber
labeling in the absence of drug treatment (note arrow in Fig. 3). Syncytia
treated with 50 nM jasplakinolide displayed decreased numbers of
stress ﬁbers as well as a relative decrease in cortical actin staining
suggesting depletion of the actin network underneath the membrane.
Treatment with 200 nM jasplakinolide resulted in marked disturbance
of the actin cytoskeleton and the presence of ﬂocculent phalloidin-
positive inclusions surrounding the nuclei (Fig. 3, note arrowheads).
These amorphousmasses of F-actin have previously been reportedupon
treatment with jasplakinolide and result from ectopic actin polymer-
ization (Bubb et al., 2000). Syncytia began to lose contact with substrate
and retract, leading to a stellate appearance of the syncytium. Cells
treated with this higher dose were fragile and easily fragmented or
washed off the coverslips during staining (data not shown).
Cytoskeletal changes in syncytium treated with latrunculin A were
more subtle than those seenwith jasplakinolide. Treatmentwith 50 nM
latrunculin A resulted in amodest loss of ﬁne actin structures, leading to
decreases in overall actin staining (Fig. 3). Treatment with 200 nM
latrunculin A resulted in complete loss of ﬁne F-actin structures, and a
marked increase rufﬂing at the cell surface (Fig. 3, note asterisk). An
increased number of cells with two nuclei were noted (data not shown)
after latrunculin A treatment, consistent with effects on cell division. A
small number of multinucleated syncytia were also observed (Fig. 3).Fig. 4. Reporter gene assays were performed in the presence of jasplakinolide or
latrunculin A at the indicated doses. Both target and effector cell populations were drug
treated for 3 h prior to and throughout the overlay. Six independent replicates of each
experimentwere conducted. Backgroundwas subtracted, and the resultswerenormalized
to those of the DMSO-treated control (RLU values for the DMSO-treated control ranged
from 3.46 to 15.48 for the jasplakinolide experiment and from 4.08 to 15.47 for the
latrunculin experiments). Error bars represent the standard error of the mean.Reporter gene assays in the presence of jasplakinolide and latrunculin A
The observed increases in syncytium formation could be the result of
an increase in the number of fusion events occurring. Alternatively, the
rate of large scale cellular reorganization subsequent to the fusion event
itself may have increased, allowing earlier visualization of the syncytia.
To discriminate between these possibilities, we employed a reporter
gene assay in which an effector cell population was cotransfected with
the viral fusion and attachment proteins, as well as a ﬁreﬂy luciferase
gene under the control of a T7 promoter. The effector cell population
was then overlaid with a target cell population which stably expresses
the T7polymerase. Luciferase signal, therefore, requires only fusionpore
enlargement sufﬁcient to pass the T7 polymerase. In this assay both
target and effector cell populations were pretreated with drug for 3 h
prior to overlay. Cells were then overlaid for 3 h prior to cell lysis and
assayed for luciferase activity.
Treatment with relatively low doses of jasplakinolide resulted in a
marked stimulation of luciferase activity with an approximate 1.8-fold
stimulation in PIV5 F-promoted fusion (Fig. 4A upper panel). This effect
peaked at 100 nM jasplakinolide, with the increases at this dose
consistent with the stimulation observed in syncytia assays. Increasing
concentrations beyond 100 nM resulted in a steady fall off in fusion
activity, potentially due to the large changes in cell morphology noted
earlier.
Latrunculin A also stimulated fusion induced by the PIV5 glycopro-
teins at low doses (Fig. 4B lower panel), as measured by the reporter
gene assay, in contrast to the lack of obvious stimulation of syncytia
formation (Fig. 2B). Latrunculin A stimulation peaked at approximately
1.6 times the control signal at a concentration of 100 nM. Increasing
doses above 100 nM also led to a gradual decrease in fusion at higher
concentrations.Treatment with jasplakinolide or latrunculin A does not affect PIV5 F
surface density
Higher surface densities of the PIV5 F protein have been shown to
increase the number of fusion events promoted by the PIV5 fusion
system (Dutch et al., 1998). Increasing surface density of the fusion
proteins therefore represents a possible explanation for the stimulation
of fusion we observed with actin drug treatment. We therefore
employed both surface biotinylation and ﬂow cytometry to investigate
potential changes that drug treatment may have had on surface
densities and cleavage state of the PIV5 F protein.
For ﬂow cytometry, cells transiently expressing PIV5 F were treated
with either latrunculin A or jasplakinolide, and analyzed using the F1a
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PIV5 F showed onlyminor decreases at doses of both jasplakinolide and
latrunculin A that produced stimulation of fusion. As the drug dose rose
to levels which inhibit fusion, a progressive fall in surface density was
seen, suggesting that the decrease in fusion may be the result of
decreases in surface density of the fusion protein.
To conﬁrm the ﬂow cytometry results, and probe for alterations in
proteolytic activation of the F protein that could result in fusion
decreases, surface biotinylation was performed. Transfected cells were
metabolically labeled with Trans-35S, and treated with drug. Surface
populations were identiﬁed using a membrane impermeable biotinyla-
tion agent (Sulfo-NHS biotin). Cells were then lysed and total and
surface protein amounts were compared. Treatment with the indicated
doses of jasplakinolide and latrunculin A did not signiﬁcantly alter
surface expression levels of the PIV5 protein in the dose ranges
examined (Fig. 5B). There was no apparent change in either theFig. 5. A. Vero cells were transfected with pCAGGS PIV5 F. The following day, cells were
treated with indicated doses of jasplakinolide or latrunculin A for 3 h. Following drug
treatment cells were stained with F1a primary, and goat anti-mouse FITC conjugated
secondary, and analyzed by ﬂow cytometry. Mean ﬂuorescent intensity (MFI) was
normalized to carrier treated control (n=4, range of MFI values for DMSO-treated
control from 99.82 to 348.6). Error bars represent standard error of the mean. B. Cells
transiently expressing PIV5 F were treated with jasplakinolide or latrunculin A, and
metabolically labeled with trans-35S. Surface biotinylation was performed and PIV5 F
protein was immunoprecipitated, streptavidin pull-downs performed, and the
resulting samples resolved with 15% SDS-PAGE.uncleaved (F0) or the cleaved, active form of the protein (F1, F2) at the
cell surface. These data demonstrate that the stimulation of fusion seen
in the previous experiments are likely not due to alterations in cell
surface concentrations or cleavage state of the PIV5 F protein. The
decrease in PIV5 F cell surface expression seen with ﬂow cytometry at
high doses of jasplakinolide and latrunculin A, but not apparent with
surface biotinylation may represent the increased sensitivity of the
method to detect changes in the levels of cell surface proteins.
Jasplakinolide and lantrunculin A stimulate pore enlargement
Paramyxovirus fusion proteins go through a series of well-deﬁned
steps during the process of fusion promotion (Fig. 1). After a proteolytic
processing event, the fusion protein exists in a metastable state.
Following a triggering event, conformational changes in the F protein
lead to insertion of the fusion peptide into the target membrane,
forming a membrane bridging conformation (Asano and Asano, 1985)
(Fig. 1). This initial triggering event can be blocked by incubation at
lowered temperature (Russell et al., 2001). The bridging conformation
then undergoes a refolding process whereby the C-terminal heptad
repeat regions fold back onto the N-terminal heptad repeat regions to
form a very stable six-helix bundle (Fig. 1). The refolding reaction can be
inhibited by treatment with peptides derived from the heptad repeat
regions which bind speciﬁcally to their complementary regions in the
fusion protein, trapping the protein in a pre-hairpin conformation
(Russell et al., 2001). The ﬁnal step in the fusion process is the
enlargement of the nascent fusion pore (Fig. 1). This ﬁnal step is poorly
understood, but truncation of the PIV5 cytoplasmic tail has been shown
to speciﬁcally affect pore enlargement (Dutch and Lamb, 2001).
To characterize the mechanism by which actin destabilizing drugs
stimulate fusion, a series of reporter gene experiments blocking speciﬁc
steps of the PIV5 F protein fusion processwere performed. Lowering the
incubation temperature from 37 °C to 30 °C immediately following the
mixing of the cell populations leads to a nearly complete inhibition of F
protein speciﬁc cell–cell fusion events (West et al., 2005). The
relationship between temperature and fusion is evident by the
similarity of luciferase signal from F and HN expressing cells compared
to negative control cell expressing HN alone (Fig. 6A, Temperature
inhibition). Treatment with jasplakinolide did not signiﬁcantly alter the
low level of fusion, suggesting that our observed stimulation of fusionby
this drug is not the result of lowering the energetic threshold for the
activation of the fusion protein. In addition, these results indicate that
jasplakinolide-induced stimulation of fusion is dependent on triggering
of the fusion protein.
Insertion of the fusion peptide into membranes has a marked
destabilizing inﬂuence on model membranes and is sufﬁcient to
promote fusion of small unilamellar vesicles (Rapaport and Shai,
1994). To determine if membrane destabilization caused by fusion
peptide insertion is sufﬁcient to allow for latrunculin A or jasplakino-
lide-induced stimulation, we examined the effect of these drugs in the
presence of the heptad repeat 2 (HR2)-derived C1 peptide. Addition of
this peptidedoes not block the initial conformational changes that result
in fusion peptide insertion. Instead, the C1 peptide is hypothesized to
arrest the fusion protein at a pre-hairpin conformation by interacting
with the N-terminal heptad repeat coiled-coil formed after the initial
conformational changes. Treatment with this peptide effectively blocks
lipidmixingpromotedby PIV5 F (Russell et al., 2001). Addition of 50 µM
C1 leads to an approximately 80% inhibition in fusion activity as
measured by reporter gene activity (Fig. 6, Peptide inhibition).
Treatment with 50 nM jasplakinolide or latrunculin A in the presence
of the inhibitory peptide was unable to signiﬁcantly increase fusion
above these levels.
Deletion of the cytoplasmic tail of the PIV5 fusionprotein (PIV5Tail−)
leads to a protein which promotes mixing of lipids and small aqueous
dyes with kinetics similar to the wild-type protein (Dutch and Lamb,
2001). However, PIV5 F Tail− is signiﬁcantly debilitated in reporter gene
Fig. 6. A. Cells expressing either PIV5 HN protein alone or the PIV5 F and HN proteins together were utilized for reporter gene analysis, as previously described, except that an
incubation temperature of 30 °C was used. Jasplakinolide (50 nM) was added to the indicated samples. Six independent experiments were performed, and in each case luciferase
activity was normalized to F+HN (RLU values for F+HN ranged from 0.78 to 1.56). Error bars represent the standard error of the mean. B. Cells expressing the PIV5 F and HN
proteins were treated with 50 nM jasplakinolide or latrunculin A, and 50 µM C1 peptide, and fusion measured by reporter gene analysis. Results from four independent experiments
were each normalized to F+HN (RLU values for F+HN 4.47 to 5.11). C and D. Reporter gene assay using wild-type PIV5 F or the mutant PIV5 F tail−. The assay was performed 11
times with the indicated doses of jasplakinolide (C) and six times for latrunculin A (D). Results were normalized to the F+HN samples (RLU values from 5.35 to 8.61 for the
jazplakinolide experiments and from 7.22 to 17.56 for the latrunculin experiments). p values are indicated for statistically signiﬁcant differences, and error bars represent standard
error of the mean.
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defect in pore enlargement. To determine whether jasplakinolide or
latrunculin A could rescue a defect in pore enlargement, we examined
PIV5 F tail− in a reporter gene assay (Fig. 6, Tail minus mutant).
Interestingly, treatment with low dose jasplakinolide and latrunculin A
resulted in a partial rescue of reporter gene activity (p=0.004 and
p=0.037, respectively). Partial, rather than full restoration may indicate
that the cytoplasmic tail of the fusion protein plays an additional role in
fusion unrelated to the actin cytoskeleton. Alternatively, these lower drug
concentrations, while not toxic to the cell or affecting fusion protein
surface expression, may not be sufﬁcient to completely remove the actin
barrier. This result does suggest that jasplakinolide and latrunculin Astimulate fusion by relieving a barrier to pore enlargement, which occurs
naturally as a consequence of the dense cortical actin layer beneath the
plasma membrane.
Discussion
We have shown that treatment with low doses of jasplakinolide
can stimulate PIV5 glycoprotein-mediated fusion events. This stimu-
lation requires the activation and subsequent conformational rear-
rangements of the PIV5 F protein (Fig. 6), suggesting that the effect
occurs late during the fusion process. We hypothesize that the
stimulatory mechanism of these drugs may be due to a decrease in a
124 M.A. Wurth et al. / Virology 404 (2010) 117–126mechanical barrier at themembranewhich is inhibitory to fusion pore
enlargement by globally decreasing the bulk of cortical actin present
at the membrane. Pore enlargement appears to be the most
energetically costly step of viral mediated membrane fusion (Cohen
and Melikyan, 2004), and a signiﬁcant portion of the energy released
upon formation of the six-helix bundle is likely required for pore
enlargement rather than membranemerger. Overcoming the physical
barrier of the cortical cytoskeleton at the membrane may provide one
possible explanation for this energetic barrier.
The observation that both latrunculin A and jasplakinolide stimulate
PIV5 Fprotein-promoted fusion, asmeasuredbya reporter gene assay, is
at ﬁrst puzzling, as the drugs have very different mechanisms of action.
Both drugs, however, do result in the depletion of the cellular free actin
pool, and treatment with jaspkalinolide (Bubb et al., 2000) or
latrunculin can result in disruption (Wakatsuki et al., 2001) of the
actin cytoskeleton. Latrunculin A accomplishes this by directly seques-
tering G-actin, while jasplakinolide ties up cellular actin in F-actin
inclusions within the cell. Even in contact-inhibited cells, the cortical
actin meshwork undergoes rapid turnover (Ponti et al., 2003). By
decreasing thepool of available actinmonomers in the cell, the structure
of the cortical actin cytoskeleton is rapidly altered.We hypothesize that
these alterations to the cortical actin structures lead to the increased
fusion that we see upon treatment with these drugs.
Interestingly, the effect of latrunculin treatment on PIV5 F protein-
promoted fusiondifferedbetween the twoassays utilized.Nosigniﬁcant
stimulation was observed in syncytia assays following latrunculin
treatment (Fig. 2), but stimulation was observed in the reporter gene
assay at similar concentrations (Fig. 4).While syncytia formation occurs
betweenattachedcells, reporter geneanalysismeasures fusionbetween
attached cells expressing the viral glycoproteins and target cells which
have been trypsinized and then added to the effector cells. Trypsin
treatment has been reported to result in disorganization of the actin
cytoskeleton (Pollack and Rifkin, 1975; Richard et al., 2009), and thus
the alterations to the actin cytoskeleton are likely greater in the target
cells in the reporter gene assay than in the cells studied for syncytia
formation.
Studies ofmyoblast fusion suggest that actin either serves asabarrier
(Richardson et al., 2007), is involved in a priming step prior to fusion
(Kim et al., 2007), or provides the needed force to expand the fusion
pore (Massarwa et al., 2007). Conﬂicting conclusions have also been
drawn concerning the role of actin in other fusion events (Eitzen, 2003).
Recent studies of both the inﬂuenza HA protein (Richard et al., 2009)
and the baculovirus gp64 protein (Chen et al., 2008) suggest that the
actin cytoskeleton serves as a barrier to fusion pore expansion,
consistentwith theﬁndingspresentedhere. Thus, the actin cytoskeleton
restricts fusion promoted by three different class 1 fusion proteins from
three viral families, suggesting a conserved mechanism of fusion.
While the larger picture of the role of actin in fusion appears similar,
the speciﬁc drug effects noted differ between our studies and others. In
particular, while we observed stimulation with jasplakinolide (Figs. 2
and 3), inhibitionwith this drugwas reported for gp64-mediated fusion
(Chenet al., 2008) andHIVenv-mediated fusion (Pontowetal., 2004). In
the gp64 study (Chen et al., 2008) 500 nMjasplakinolidewas employed,
which is signiﬁcantly higher than the concentrations used in our
experiments. Indeed, we observed similar decreases in fusion with
400 nM jaspakinolide (Fig. 4), though we also found alterations in cell
morphology and reductions in cell surface expression of the F protein
(Fig. 5A) that complicate any conclusions on the direct effect of higher
concentrations of jazplakinolide on PIV5 F protein-promoted fusion.
Jasplakinolide inhibition of HIV env-promoted cell–cell fusion also
occurred at higher concentrations (500 nm–1 µM), though no stimula-
tion was observed with lower concentrations (Pontow et al., 2004), in
contrast to our ﬁndings. Latrunculin A at 2 µM was found to greatly
increase pore expansion in gp64-promoted membrane fusion, while
similar concentrations completely inhibited HIV env-promoted fusion
(Pontow et al., 2004). In our study, stimulation was observed at lowerlevels, but higher concentrations lead to inhibition and large changes in
cell morphology (Fig. 3). The inherent differences between the Sf9 host
cells utilized in the gp64 experiments and the BHK and astroglioma cell
lines utilized here and in the HIV env study may account for these
differences. Alterations in the inhibitory/stimulatory effect of these
drugs under different experimental conditions have been observed in
studies of fusion in exocytosis (Eitzen, 2003).
Deletion of nineteen of the twenty amino acids of the cytoplasmic
domain of PIV5 F leads to a speciﬁc defect in pore enlargement (Dutch
and Lamb, 2001). It would be possible for this domain to interact with
proteins in the cytosol of the target cell upon formation of the nascent
fusion pore, thereby providing a platform for signaling to drive
alterations in the cytoskeleton which could facilitate membrane fusion.
Interestingly, recombinant viruses containing an F protein with an 18-
amino acid C-tail deletion were only minorly debilitated for fusion,
while those with a 20 amino acid deletion showed surface expression
alterations for the F protein, andwere therefore not examined for fusion
(Waning et al., 2002). These results suggest that either other viral
proteins, such as thematrix protein, can partially compensate for loss of
the F protein cytoplasmic tail, or that the two cytoplasmic tail residues
closest to the membrane are those critically important in fusion.
Examination of this region for interactions with cellular proteins and
study of the role of actin in the context of viral infection represent
signiﬁcant areas worthy of further study.
Materials and methods
Cell lines
Baby hamster kidney (BHK) and Vero cells were maintained in
Dulbecco's modiﬁed Eagle's medium (DMEM; Gibco Invitrogen,
Carlsbad, California) supplemented with fetal bovine serum (FBS
[10%]), penicillin (1%), and streptomycin (1%) (P/S). BSR cells, derived
from BHK cells and constitutively expressing the T7 polymerase
(Buchholz et al., 1999) (kindly provided by Karl-Klaus Conzelmann,
Max Pettenkofer Institute) were similarly passaged, by selection with
0.5 mg/ml G418 every third passage.
Drug preparation
Latrunculin A and jasplakinolide were purchased from Calbiochem.
Drugs were diluted to 50 µM working stocks in DMSO. C1 peptide was
prepared as previously described (Joshi et al., 1998).
Syncytium assay
Subconﬂuent monolayers of BHK cells in six-well plates were
transiently transfected with pCAGGS (2 µg) or pCAGGS PIV5 F (1 µg)
and pCAGGS PIV5 HN (1 µg) using Lipofectamine Plus (Life Technolo-
gies) according to themanufacturer's protocol. Cellswere then returned
to DMEMwith FBS and P/S supplementedwith drug or the drug carrier,
DMSO. Syncytia were allowed to develop overnight and photomicro-
graphs were taken the following day using a Nikon Diaphot inverted
phase-contrast microscope.
Immunoﬂuorescence
Vero cells were grown on polylysine coated coverslips. Cells were
transfected and treated as in the syncytium assay. Syncytia were
allowed to develop overnight. The following day cells were ﬁxed in 4%
paraformaldehyde. All cells were stained with rhodamine–phalloidin
(Invitrogen) and mounted in Vectashield with DAPI (Vector Labs).
Cells were imaged on a Zeiss Axiovert 200 M inverted ﬂuorescence
microscope (Carl Zeiss Microimaging, Thornwood, NY) using an Orca
ER camera (Hamamatsu Corp. Bridgewater, NJ).
125M.A. Wurth et al. / Virology 404 (2010) 117–126Reporter gene assay
Six well plates of subconﬂuent Vero cells were transfected with
1 µg pCAGGS PIV5 F, 1 µg pCAGGS PIV5 HN, and 0.8 µg T7-Control
(containing the ﬁreﬂy luciferase gene under the control of a T7
promoter) on the day prior to performing the assay. Background
signal was determined by replacing the fusion protein construct with
empty pCAGGS vector. The day following transfection, BSR cells were
trypsinized, washed once, and resuspended in DMEM+10% FBS+1%
P/S supplemented with drug or DMSO. At the same time, the effector
cell population was transferred to media supplemented with drug or
DMSO. Both effector cell and target cell populations were maintained
in drug for 3 h prior to overlay. Target cells were maintained in
suspension by periodic agitation. Target cells were then plated onto
effector cells and 3 h later the mixed cell population was lysed and
assayed using the luciferase assay kit (Promega). Luminometry was
performed on an Lmax luminometer (Molecular Devices, Sunnyvale,
CA). For all reporter gene data, with the exception of the temperature
inhibition study, background luciferase activity was subtracted from
speciﬁc fusion induced activity. Each replicate was then normalized to
signal measured with F and HN in the presence of DMSO, since
signiﬁcant changes in absolute time-integrated luminescence were
seen between independent experiments while the trend remained
consistent. Data was then averaged over all replicates and standard
error of the mean and the statistical difference between populations
were calculated using paired t-tests and ANOVA analysis using
KaleidaGraph (Synergy Software, Reading, PA). Temperature blockade
data was normalized as described, though without background
subtraction, as signal was compared to background.
Temperature or peptide-mediated inhibition of membrane fusion
For studies on the effect of temperatures, reporter gene assays
were performed as above with the exception that all media was
maintained at room temperature and incubator temperature was
lowered to 30 °C for the drug incubation, and overlay. For studies on
the effect of peptide addition, lyophilized C1 peptide, prepared as
previously described (Joshi et al., 1998) was dissolved in phosphate
buffered saline and the peptide concentration was determined by
280 nm absorbance in 6 M guanidine. At the time of overlay themedia
was supplemented with PBS or PBS with C1 peptide to a ﬁnal peptide
concentration of 50 µM.
Flow cytometry
Flow cytometry was performed as previously described (Schowalter
et al., 2006). Brieﬂy 6 cm plates of Vero cells were transfected with
either 4 µgof pCAGGSPIV5 F or pCAGGSemptyvector. Cellswereplaced
in media containing drug or DMSO 3 h prior to staining. At the time of
staining cells were moved to 4 °C. Cells were stained with F1a
monoclonal antibody (kindly provided by Dr. Richard Randall, Univer-
sity of St. Andrews) against PIV5 F and goat anti-mouse FITC conjugated
secondary antibody. Mean ﬂuorescence intensity was measured for
10,000 cells. Mean ﬂuorescence intensity was normalized to DMSO-
treated cells. Independent replicates were averaged and standard error
of the mean was calculated using Kaleidograph.
Expression and biotinylation of cell surface proteins
Vero cells in 6 cm dishes were transiently transfected with 8 µg
pCAGGS-PIV5 F or the empty pCAGGS expression vector using
Lipofectamine 2000. At 18–24 h post-transfection, cells were starved
in methionine- and cysteine-deﬁcient DMEM for 45 min and then
metabolically labeled with Trans[35S] label (100 µCi/ml; MP Biome-
dicals) for 1 h. Cells were washed once with PBS, then incubated in
2 ml/dish DMEM plus FBS and P/S containing 0–200 nM latrunculin Aor jazplakinolide for 3 h. Cells were washed three times with cold pH
8 PBS and incubated with 1 mg/ml EZ-Link Sulfo-NHS-Biotin (Pierce,
Rockford, IL) diluted in pH 8 PBS for 10 min rocking at 4 °C, then
20 min at room temperature. Cells were washed three times again
with pH 8 PBS, then lysed in RIPA buffer containing 100 mM Tris–HCl
(pH 7.4), 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% Triton
X-100, 1% deoxycholic acid, protease inhibitors (1 KalliKrein inhib-
itory unit of aprotinin [Calbiochem, San Diego, Calif.], 1 mM
phenylmethylsulfonyl ﬂuoride [Sigma, St. Louis, Mo.]), and 25 mM
iodoacetamide (Sigma). The lysates were centrifuged at 136,500×g
for 10 min at 4 °C, and supernatants were collected. Antipeptide sera
directed against the PIV5 F cytoplasmic tails and protein A-conjugated
sepharose beads (Amersham, Piscataway, N.J.) were used to immu-
noprecipitate the F protein as previously described (Paterson and
Lamb, 1993). Sepharose beads were boiled twice in 10% SDS for
10 min to release protein. Fifteen percent of total protein was
removed for analysis, and the remaining 85% was incubated with
immobilized streptavidin (Pierce) for 1 h at 4 °C, then biotin-labeled
protein bound to streptavidin was pulled-down and analyzed via SDS-
15% polyacrylamide gel electrophoresis (SDS-PAGE) and visualized
using the Typhoon imaging system.Acknowledgments
We are grateful to members of the Dutch lab for critically reviewing
this manuscript. Imaging studies were funded in part due to grants for
the imaging facility provided by NIH COBRE grant P20RR20171. This
study was supported by NIAID grant R01A151517 to R.E.D., NEI grant
R21 YE018112 to CLM, and NIH grant P20RR20171 to ROM.References
Asano, K., Asano, A., 1985. Why is a speciﬁc amino acid sequence of F glycoprotein
required for the membrane fusion reaction between envelope of HVJ (Sendai virus)
and target cell membranes? Biochem. Int. 10, 115–122.
Baker, K.A., Dutch, R.E., Lamb, R.A., Jardetzky, T.S., 1999. Structural basis for
paramyxovirus-mediated membrane fusion. Mol. Cell 3, 309–319.
Bishop, A.L., Hall, A., 2000. Rho GTPases and their effector proteins. Biochem. J. 348 (Pt 2),
241–255.
Black, C.P., 2003. Systematic review of the biology and medical management of
respiratory syncytial virus infection. Respir. Care 48 (3), 209–231 discussion 231-3.
Bubb, M.R., Senderowicz, A.M., Sausville, E.A., Duncan, K.L., Korn, E.D., 1994.
Jasplakinolide, a cytotoxic natural product, induces actin polymerization and
competitively inhibits the binding of phalloidin to F-actin. J. Biol. Chem. 269 (21),
14869–14871.
Bubb, M.R., Spector, I., Beyer, B.B., Fosen, K.M., 2000. Effects of jasplakinolide on the
kinetics of actin polymerization. An explanation for certain in vivo observations.
J. Biol. Chem. 275 (7), 5163–5170.
Buchholz, U.J., Finke, S., Conzelmann, K.K., 1999. Generation of bovine respiratory
syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in
tissue culture, and the human RSV leader region acts as a functional BRSV genome
promoter. J. Virol. 73, 251–259.
Chen, A., Leikina, E., Melikov, K., Podbilewicz, B., Kozlov, M.M., Chernomordik, L.V.,
2008. Fusion-pore expansion during syncytium formation is restricted by an actin
network. J. Cell Sci. 121 (Pt 21), 3619–3628.
Chernomordik, L.V., Sowers, A.E., 1991. Evidence that the spectrin network and a
nonosmotic force control the fusion product morphology in electrofused
erythrocyte ghosts. Biophys. J. 60 (5), 1026–1037.
Chernomordik, L.V., Zimmerberg, J., Kozlov, M.M., 2006. Membranes of the world unite!
J. Cell Biol. 175 (2), 201–207.
Chua, K.B., Goh, K.J., Wong, K.T., Kamarulzaman, A., Tan, P.S., Ksiazek, T.G., Zaki, S.R.,
Paul, G., Lam, S.K., Tan, C.T., 1999. Fatal encephalitis due to Nipah virus among pig-
farmers in Malaysia. Lancet 354 (9186), 1257–1259.
Cohen, F.S., Melikyan, G.B., 2004. The energetics of membrane fusion from binding,
through hemifusion, pore formation, and pore enlargement. J. Membr. Biol. 199 (1),
1–14.
Coue, M., Brenner, S.L., Spector, I., Korn, E.D., 1987. Inhibition of actin polymerization by
latrunculin A. FEBS Lett. 213 (2), 316–318.
Dutch, R.E., Jardetsky, T.S., Lamb, R.A., 2000. Virus membrane fusion proteins: biological
machines that undergo a metamorphosis. Biosci. Rep. 20 (6), 597–612.
Dutch, R.E., Joshi, S.B., Lamb, R.A., 1998. Membrane fusion promoted by increasing
surface densities of the paramyxovirus F and HN proteins: comparison of fusion
reactions mediated by simian virus 5 F, human parainﬂuenza virus type 3 F, and
inﬂuenza virus HA. J. Virol. 72 (10), 7745–7753.
126 M.A. Wurth et al. / Virology 404 (2010) 117–126Dutch, R.E., Lamb, R.A., 2001. Deletion of the cytoplasmic tail of the fusion (F) protein of
the paramyxovirus simian virus 5 (SV5) affects fusion pore enlargement. J. Virol.
75, 5363–5369.
Dutch, R.E., Leser, G.P., Lamb, R.A., 1999. Paramyxovirus fusion protein: characterization
of the core trimer, a rod-shaped complex with helices in anti-parallel orientation.
Virology 254, 147–159.
Eaton, B.T., Broder, C.C., Middleton, D., Wang, L.F., 2006. Hendra and Nipah viruses:
different and dangerous. Nat. Rev. Microbiol. 4 (1), 23–35.
Eitzen, G., 2003. Actin remodeling to facilitate membrane fusion. Biochim. Biophys. Acta
1641 (2–3), 175–181.
Garten, W., Hallenberger, S., Ortmann, D., Schafer, W., Vey, M., Angliker, H., Shaw, E.,
Klenk, H.D., 1994. Processing of viral glycoproteins by the subtilisin-like
endoprotease furin and its inhibition by speciﬁc peptidylchloroalkylketones.
Biochimie 76 (3–4), 217–225.
Goswami, K.K.A., Lange, L.S., Mitchell, D.N., Cameron, K.R., Russell, W.C., 1984. Does
simian virus 5 infect humans. J. Gen. Virol. 65, 1295–1303.
Gower, T.L., Pastey, M.K., Peeples, M.E., Collins, P.L., McCurdy, L.H., Hart, T.K., Guth, A.,
Johnson, T.R., Graham, B.S., 2005. RhoA signaling is required for respiratory syncytial
virus-induced syncytium formation and ﬁlamentous virion morphology. J. Virol. 79
(9), 5326–5336.
Joshi, S.B., Dutch, R.E., Lamb, R.A., 1998. A core trimer of the paramyxovirus fusion protein:
parallels to inﬂuenza virus hemagglutinin and HIV-1 gp41. Virology 248, 20–34.
Kallewaard, N.L., Bowen, A.L., Crowe Jr., J.E., 2005. Cooperativity of actin and microtubule
elements during replication of respiratory syncytial virus. Virology 331 (1), 73–81.
Kim, S., Shilagardi, K., Zhang, S., Hong, S.N., Sens, K.L., Bo, J., Gonzalez, G.A., Chen, E.H.,
2007. A critical function for the actin cytoskeleton in targeted exocytosis of
prefusion vesicles during myoblast fusion. Dev. Cell 12 (4), 571–586.
Lamb, R.A., Jardetzky, T.S., 2007. Structural basis of viral invasion: lessons from
paramyxovirus F. Curr. Opin. Struct. Biol. 17 (4), 427–436.
Lamb, R.A., Parks, G.D., 2007. Paramyxoviridae: the viruses and their replication. In:
Knipe, D.M., Howley, P.M. (Eds.), Fields Virology, vol. 1, pp. 1449–1496. 2 vols.
Makino, S., Yamaguchi, F., Sata, T., Urushibata, O., Kurata, T., Nishiwaki, M., 1994. The
rash of measles is caused by a viral infection in the cells of the skin: a case report. J.
Dermatol. 21 (10), 741–745.
Massarwa, R., Carmon, S., Shilo, B.Z., Schejter, E.D., 2007. WIP/WASp-based actin-
polymerization machinery is essential for myoblast fusion in Drosophila. Dev. Cell
12 (4), 557–569.
McCandlish, I.A., Thompson, H., Cornwell, H.J., Wright, N.G., 1978. A study of dogs with
kennel cough. Vet. Rec. 102 (14), 293–301.
Meyerholz, D.K., Grubor, B., Fach, S.J., Sacco, R.E., Lehmkuhl, H.D., Gallup, J.M.,
Ackermann, M.R., 2004. Reduced clearance of respiratory syncytial virus infection
in a preterm lamb model. Microbes Infect. 6 (14), 1312–1319.
Muallem, S., Kwiatkowska, K., Xu, X., Yin, H.L., 1995. Actin ﬁlament disassembly is a
sufﬁcientﬁnal trigger for exocytosis innonexcitable cells. J. Cell Biol. 128 (4), 589–598.
Niwa, H., Yamamura, K., Miyazaki, J., 1991. Efﬁcient selection for high-expression
transfectants by a novel eukaryotic vector. Gene 108, 193–200.
Novick, S.L., Hoekstra, D., 1988. Membrane penetration of Sendai virus glycoproteins
during the early stage of fusion with liposomes as determined by hydrophobic
afﬁnity labeling. Proc. Natl. Acad. Sci. U.S.A. 85, 7433–7437.
Pager, C.T., Dutch, R.E., 2005. Cathepsin L is involved in proteolytic processing of the
Hendra virus fusion protein. J. Virol. 79 (20), 12714–12720.
Paterson, D.L., Murray, P.K., McCormack, J.G., 1998. Zoonotic disease in Australia caused
by a novel member of the Paramyxoviridae. Clin. Infect. Dis. 27 (1), 112–118.
Paterson, R.G., Lamb, R.A., 1993. The molecular biology of inﬂuenza viruses and
paramyxoviruses. In: Davidson, A., Elliott, R.M. (Eds.), Molecular Virology: A
Practical Approach. IRL Oxford University Press, Oxford, England, pp. 35–73.Paton, N.I., Leo, Y.S., Zaki, S.R., Auchus, A.P., Lee, K.E., Ling, A.E., Chew, S.K., Ang, B., Rollin, P.
E., Umapathi, T., Sng, I., Lee, C.C., Lim, E., Ksiazek, T.G., 1999. Outbreak of Nipah-virus
infection among abattoir workers in Singapore. Lancet 354 (9186), 1253–1256.
Pollack, R., Rifkin, D., 1975. Actin-containing cables within anchorage-dependent rat
embryo cells are dissociated by plasmin and trypsin. Cell 6, 495–506.
Ponti, A., Vallotton, P., Salmon, W.C., Waterman-Storer, C.M., Danuser, G., 2003.
Computational analysis of F-actin turnover in cortical actin meshworks using
ﬂuorescent speckle microscopy. Biophys. J. 84 (5), 3336–3352.
Pontow, S.E., Heyden, N.V., Wei, S., Ratner, L., 2004. Actin cytoskeletal reorganizations
and coreceptor-mediated activation of rac during human immunodeﬁciency virus-
induced cell fusion. J. Virol. 78 (13), 7138–7147.
Randall, R.E., Young, D.F., Goswami, K.K.A., Russell, W.C., 1987. Isolation and
characterization of monoclonal antibodies to simian virus 5 and their use in
revealing antigenic differences between human, canine and simian isolates. J. Gen.
Virol. 68, 2769–2780.
Rapaport, D., Shai, Y., 1994. Interaction of ﬂuorescently labeled analogues of the amino-
terminal fusion peptide of Sendai virus with phospholipid membranes. J. Biol.
Chem. 269 (21), 15124–15131.
Richard, J.P., Leikina, E., Chernomordik, L.V., 2009. Cytoskeleton reorganization in
inﬂuenza hemagglutinin-initiated syncytium formation. Biochim. Biophys. Acta
1788 (2), 450–457.
Richardson, B.E., Beckett, K., Nowak, S.J., Baylies, M.K., 2007. SCAR/WAVE and Arp2/3
are crucial for cytoskeletal remodeling at the site of myoblast fusion. Development
134 (24), 4357–4367.
Richardson, B.E., Nowak, S.J., Baylies, M.K., 2008. Myoblast fusion in ﬂy and vertebrates:
new genes, new processes and new perspectives. Trafﬁc 9 (7), 1050–1059.
Russell, C.J., Jardetzky, T.S., Lamb, R.A., 2001. Membrane fusion machines of
paramyxoviruses: capture of intermediates of fusion. EMBO J. 20 (15), 4024–4034.
Scheid, A., Choppin, P.W., 1974. Identiﬁcation of biological activities of paramyxovirus
glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic
cleavage of an inactive precursor protein of Sendai virus. Virology 57, 475–490.
Schowalter, R.M.,Wurth, M.A., Aguilar, H.C., Lee, B., Moncman, C.L., McCann, R.O., Dutch,
R.E., 2006. Rho GTPase activity modulates paramyxovirus fusion protein-mediated
cell–cell fusion. Virology 350, 323–334.
Spector, I., Shochet, N.R., Kashman, Y., Groweiss, A., 1983. Latrunculins: novelmarine toxins
that disruptmicroﬁlamentorganization incultured cells. Science219 (4584), 493–495.
Wakatsuki, T., Schwab, B., Thompson, N.C., Elson, E.L., 2001. Effects of cytochalasin D
and latrunculin B on mechanical properties of cells. J. Cell Sci. 114 (Pt 5),
1025–1036.
Waning, D.L., Schmitt, A.P., Leser, G.P., Lamb, R.A., 2002. Roles for the cytoplasmic tails
of the fusion and hemagglutinin-neuraminidase proteins in budding of the
paramyxovirus simian virus 5. J. Virol. 76 (18), 9284–9297.
West, D.S., Sheehan, M.S., Segeleon, P.K., Dutch, R.E., 2005. Role of the simian virus 5
fusion protein N-terminal coiled-coil domain in folding and promotion of
membrane fusion. J. Virol. 79 (3), 1543–1551.
Wolfson, L.J., Strebel, P.M., Gacic-Dobo, M., Hoekstra, E.J., McFarland, J.W., Hersh, B.S.,
2007. Has the 2005 measles mortality reduction goal been achieved? A natural
history modelling study. Lancet 369 (9557), 191–200.
Yin, H.S., Paterson, R.G., Wen, X., Lamb, R.A., Jardetzky, T.S., 2005. Structure of the
uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein. Proc. Natl.
Acad. Sci. U.S.A. 102 (26), 9288–9293.
Yin, H.S., Wen, X., Paterson, R.G., Lamb, R.A., Jardetzky, T.S., 2006. Structure of the
parainﬂuenza virus 5 F protein in its metastable, prefusion conformation. Nature
439 (7072), 38–44.
Zheng, Q.A., Chang, D.C., 1991. Reorganization of cytoplasmic structures during cell
fusion. J. Cell Sci. 100 (Pt 3), 431–442.
